Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 4/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910315 | 1.00 | TRPM8 (0.56) | TRPM8CTRB1SPPL2ACTSBACE2 | |
| SCHEMBL7698179 | 1.00 | TRPM8 (0.56) | TRPM8CTRB1SPPL2ACTSBACE2 | |
| SCHEMBL5413813 | 1.00 | TRPM8 (0.56) | TRPM8CTRB1SPPL2ACTSBACE2 | |
| SCHEMBL3029758 | 0.90 | CTSK (0.55) | CTRB1CTSBACE2CTSKCTSL | |
| SCHEMBL8478010 | 0.90 | CTRB1 (0.54) | TRPM8CTRB1SPPL2ACTSBACE2 | |
| SCHEMBL2582361 | 0.90 | SPPL2A (0.53) | TRPM8CTRB1SPPL2ACTSBACE2 | |
| SCHEMBL2577831 | 0.90 | SPPL2A (0.53) | TRPM8CTRB1SPPL2ACTSBACE2 | |
| SCHEMBL4908808 | 0.90 | SPPL2A (0.53) | TRPM8CTRB1SPPL2ACTSBACE2 | |
| SCHEMBL14395196 | 0.89 | BACE1 (0.51) | BCHEBACE1SLC6A11 | |
| SCHEMBL2601900 | 0.88 | BACE1 (0.62) | TRPM8CTRB1CTSBBCHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | TRPM8 2825/4885CTRB1 24/4885SPPL2A 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.